{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pleural+Effusion%2C+Malignant&page=2", "query": { "condition": "Pleural Effusion, Malignant", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pleural+Effusion%2C+Malignant&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T09:06:57.130Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02122185", "title": "Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brenner Tumor", "Malignant Ascites", "Malignant Pleural Effusion", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mixed Epithelial Carcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Undifferentiated Adenocarcinoma", "Recurrent Fallopian Tube Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Primary Peritoneal Cavity Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Primary Peritoneal Cavity Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Primary Peritoneal Cavity Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Primary Peritoneal Cavity Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "metformin hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 111, "start_date": "2015-02-25", "completion_date": "2024-10-08", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02122185" }, { "nct_id": "NCT02623959", "title": "Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Advanced Cancers", "Malignant Pleural Effusions" ], "interventions": [ { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Fentanyl Patch", "type": "DRUG" }, { "name": "Fentanyl (IV)", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Phone Calls", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2016-04-27", "completion_date": "2017-05-23", "has_results": true, "last_update_posted_date": "2019-08-07", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02623959" }, { "nct_id": "NCT01117740", "title": "Pleural Catheters Versus Thoracoscopic Pleurodesis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "MDASI Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 445, "start_date": "2010-04", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-04-11", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01117740" }, { "nct_id": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Anaplastic Thyroid Cancer", "Bone Metastases", "Carcinoma of the Appendix", "Distal Urethral Cancer", "Fallopian Tube Cancer", "Gastrinoma", "Glucagonoma", "Inflammatory Breast Cancer", "Insulinoma", "Liver Metastases", "Localized Unresectable Adult Primary Liver Cancer", "Lung Metastases", "Male Breast Cancer", "Malignant Pericardial Effusion", "Malignant Pleural Effusion", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Parathyroid Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Newly Diagnosed Carcinoma of Unknown Primary", "Occult Non-small Cell Lung Cancer", "Pancreatic Polypeptide Tumor", "Primary Peritoneal Cavity Cancer", "Proximal Urethral Cancer", "Pulmonary Carcinoid Tumor", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adrenocortical Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Carcinoma of Unknown Primary", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Parathyroid Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Thyroid Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Skin Metastases", "Small Intestine Adenocarcinoma", "Somatostatinoma", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Adrenocortical Carcinoma", "Stage III Bladder Cancer", "Stage III Cervical Cancer", "Stage III Colon Cancer", "Stage III Endometrial Carcinoma", "Stage III Esophageal Cancer", "Stage III Follicular Thyroid Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Pancreatic Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Prostate Cancer", "Stage III Rectal Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Anal Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Anal Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Adrenocortical Carcinoma", "Stage IV Anal Cancer", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Gastric Cancer", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Papillary Thyroid Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Urethral Cancer Associated With Invasive Bladder Cancer", "WDHA Syndrome" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "ABI-007/carboplatin/trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004074" }, { "nct_id": "NCT02135588", "title": "Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Loculated or Non-draining Malignant Pleural Effusions" ], "interventions": [ { "name": "Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Regional Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2013-10", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02135588" }, { "nct_id": "NCT00019825", "title": "Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Lung Cancer", "Malignant Mesothelioma", "Metastatic Cancer" ], "interventions": [ { "name": "decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019825" }, { "nct_id": "NCT06184321", "title": "Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Alteplase", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-08-17", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06184321" }, { "nct_id": "NCT00528645", "title": "AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer", "Lung Metastases", "Malignant Pleural Effusion", "Recurrent Small Cell Lung Cancer" ], "interventions": [ { "name": "saracatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2007-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-12-07", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00528645" }, { "nct_id": "NCT00118183", "title": "Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Lung", "Adenosquamous Cell Lung Cancer", "Large Cell Lung Cancer", "Malignant Pleural Effusion", "Recurrent Non-small Cell Lung Cancer", "Squamous Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2005-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 1, "location_summary": "Miami Beach, Florida", "locations": [ { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118183" }, { "nct_id": "NCT01004510", "title": "Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Effusion", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "zoledronic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Peter Bushunow MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2009-11", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2012-12-04", "last_synced_at": "2026-06-10T09:06:57.130Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004510" } ] }